FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington,	D.C.	20549
-------------	------	-------

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL							
OMB Number: 3235-028							
Estimated average burden							
hours per response:							

	Check this box if no longer subject to
\neg	Section 16. Form 4 or Form 5
$_{-}$	obligations may continue. See
	Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940							
2. Issuer Name and Ticker or Trading Symbol	5.						

1. Name and Address of Reporting Person* <u>JEFFS ROGER</u>					2. Issuer Name and Ticker or Trading Symbol Axsome Therapeutics, Inc. [AXSM]							(Ch	eck all applic	able) r	g Person(s) to Issu		ner
(Last)	`	,	(Middle)		3. Date of Earliest Transaction (Month/Day/Year) 03/02/2023								Officer (give title below) Other (specific below)			city	
		ERAPEUTICS, I															
22 CORTLANDT STREET, 16TH FLOOR				4	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable					
(Street)												Line	,	led by One	Reporting Pe	rson	
NEW YO	ORK N	Y	10007										Form fi Person		than One Re	porting	,
(City)	(S	tate)	(Zip)														
		Tal	ble I - Non-I	Derivati	ve Se	curities	Acc	quired,	Disp	posed of	f, or Ber	neficiall	y Owned				
Date			. Transacti ate Month/Day	Execution Date,		execution Date, fany		3. Transaction Code (Instr. 8) 4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)				es I ally (Following (6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Indir Bend Own	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
							Code	٧	Amount	(A) or (D) Price		Reported Transact (Instr. 3 a	ion(s)			u. 4)	
			Table II - De (e.							osed of, onvertib			Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Yea	Code (Instr.				6. Date Exercisable and Expiration Date (Month/Day/Year)		9	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s	Owners Form: Direct (or Indir (I) (Inst	hip of B D) O ect (li	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	v	(A)	(D)	Date Exercisab		Expiration Date	Title	Amount or Number of Shares		(Instr. 4)	in(ə /		
Stock Option (Right to	\$65.32	03/02/2023		A		2,082 ⁽¹⁾		03/02/202	13	03/01/2033	Common Stock	2,082	\$0.00	2,082	D		

Explanation of Responses:

1. Represents 2,082 options elected to be received in lieu of cash compensation earned in 2022. All of such options are immediately exercisable.

Remarks:

/s/ Herriot Tabuteau, M.D., Attorney in Fact

** Signature of Reporting Person Date

03/06/2023

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

 $^{^{\}star}$ If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

^{**} Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).